Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices

Abstract

Objectives Levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs) are designed to exhibit only local hormonal effects. There is an ongoing debate on whether LNG-IUDs can have side effects similar to systemic hormonal medication. Benign background parenchymal enhancement (BPE) in dynamic contrast–enhanced (DCE) MRI has been established as a sensitive marker of hormonal stimulation of the breast. We investigated the association between LNG-IUD use and BPE in breast MRI to further explore possible systemic effects of LNG-IUDs. Methods Our hospital database was searched to identify premenopausal women without personal history of breast cancer, oophorectomy, and hormone replacement or antihormone therapy, who had undergone standardized DCE breast MRI at least twice, once with and without an LNG-IUD in place. To avoid confounding aging-related effects on BPE, half of included women had their first MRI without, the other half with, LNG-IUD in place. Degree of BPE was analyzed according to the ACR categories. Wilcoxon-matched-pairs signed-rank test was used to compare the distribution of ACR categories with vs. without LNG-IUD. Results Forty-eight women (mean age, 46 years) were included. In 24/48 women (50% [95% CI: 35.9–64.1%]), ACR categories did not change with vs. without LNG-IUDs. In 23/48 women (48% [33.9–62.1%]), the ACR category was higher with vs. without LNG-IUDs; in 1/48 (2% [0–6%]), the ACR category was lower with vs. without LNG-IUDs. The change of ACR category depending on the presence or absence of an LNG-IUD proved highly significant (p < 0.001). Conclusion The use of an LNG-IUD can be associated with increased BPE in breast MRI, providing further evidence that LNG-IUDs do have systemic effects. Key Points • The use of levonorgestrel-releasing intrauterine contraceptive devices is associated with increased background parenchymal enhancement in breast MRI. • This suggests that hormonal effects of these devices are not only confined to the uterine cavity, but may be systemic. • Potential systemic effects of levonorgestrel-releasing intrauterine contraceptive devices should therefore be considered.

Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data

“…Common side effects include irregular bleeding, abdominal and pelvic pain, acne, ovarian cysts, and headache, and adhesion to or perforation of the uterine lining is possible [ 2 ]. While the effects of hormonal IUDs should theoretically be localized to the uterine area, studies have suggested they have more systemic impact than anticipated, including hormonal stimulation of breast tissue [ 3 , 4 ].…”